Troxacitabine in acute leukemia

Hematology

Volumn 12, Issue 3, 2007, Pages 219-227

  Swords, R ^a   Giles, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukaemia; Nucleoside analogues; Review; Troxacitabine

Indexed keywords

CAMPTOTHECIN; CYTARABINE; DIMETHYL SULFOXIDE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IMATINIB; MYELOTARG; NUCLEOSIDE ANALOG; PREDNISOLONE; PYRIDOXINE; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLISTER; BLOOD TOXICITY; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ERYTHEMA; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERPIGMENTATION; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN EXFOLIATION; SKIN TIGHTNESS; SKIN TOXICITY; SOFT TISSUE DISEASE; SOLID TUMOR; STEREOCHEMISTRY; STOMATITIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TOXIC HEPATITIS; VEIN OCCLUSION; VISCERAL METASTASIS; VOMITING;

ACUTE DISEASE; CYTOSINE; DIOXOLANES; HUMANS; LEUKEMIA; TREATMENT OUTCOME;

EID: 34250633985     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701406881     Document Type: Review

References (46)

1. Mansour, TS, Jin, H. and Wang, W. (1995) Anti-human immunodeficiency virus and anti-hepatitis B virus activities and toxicites of the enantiomers of 2-deoxy-3-oxa-4-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem, 38, pp. 1-4.
2. Giles, FJ (2002) Troxacitabine-based therapy of refractory leukemia. Expt Rev Anticancer Ther, 2:3, pp. 261-266.
3. Balzarini, J., Wedgewood, O. and Kruinig, J. (1996) Anti-HIV and anti-HBV activity and resistance profile of 2,3-dideoxy-3-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun, 225, pp. 363-369.
4. Mar, EC, Chu, CK and Lin, JC (1995) Some nucleoside analogs with anti-human immunodeficiency virus inhibit replication of epstein barr virus. Antiviral Res, pp. 1-11.
5. Coates, JA, Cammack, N. and Jenkinson, HJ (1992) (-)-2-deoxy-3-thiacytidine is a potent highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother, pp. 733-739.
6. Alves, AJ (1992) Potent anti-HIV and anti-HBV activites of (-)-beta-dioxolane-C and (+)--beta-dioxolane-T and their asymmetric synthesis. Tetrahedron Lett, 33, p. 6899.
7. Grove, KL (1995) Anticancer activity of beta-dioxolane-cytidine, a novel nucleoside analogue with the unnatural configuration. Cancer Res, 55:14, pp. 3008-3011.
8. Grove, KL and Cheng, YC (1996) Uptake and metabolism of the new anticancer compound beta-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res, 56:18, pp. 4187-4191.
9. Siu, LL (1998) Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol, 9:8, pp. 885-891.
10. Kadhim, SA (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta--dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res, 57:21, pp. 4803-4810.
11. Gourdeau, H. (2001) Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res, 61:19, pp. 7217-7224.
12. Gati, WP (1998) Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC). Leuk Lymphoma, 32:1, pp. 45-54.
13. Owens, JK, Shewach, DS and Ullman, B. (1992) Resistance to 1-beta-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer, 52, pp. 2389-2393.
14. De, BJS, Stephenson, JJR and Baker, SD (2002) Troxacitabine, an -stereoisomeric nucleoside analogue, on a five times daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol, 20, pp. 96-109.
15. Krishnan, P. (2002) Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: Selective phosphorylation of -nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem, 277:7, pp. 5453-5459.
16. Krishnan, P. (2003) Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem, pp. 36726-36732.
17. Moore, LE, Boudinot, FD and Chu, CK (1997) Preclinical pharmacokinetics of beta-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother Pharmacol, 39:6, pp. 532-536.
18. Kukhanova, M. (1995) L- and D-enantiomers of 2′,3′-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem, 270:39, pp. 23055-23059.
19. Chou, KM, Kukhanova, M. and Cheng, YC (2000) A novel action of human apurinic/apyrimidinic endonuclease: Excision of -configuration deoxyribonucleoside analogs from the 3' termini of DNA. J Biol Chem, 275:40, pp. 31009-31015.
20. Grant, S. (1998) Ara-C: Cellular and molecular pharmacology. Adv Cancer Res, 72, pp. 197-233.
21. Gourdeau, H. (2001) Comparative study of a novel nucleoside analogue (troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol, 47:3, pp. 236-240.
22. Weitman, S. (2000) The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res, 6:4, pp. 1574-1578.
23. Schwartz, PM, Haggerty, JG and Cheng, YC (1998) Beta-1,3-dioxolane-cytidine: A novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol Appl Skin Physiol, 11:4, pp. 207-213.
24. Rabbani, SA (1998) Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res, 58:15, pp. 3461-3465.
25. Bouffard, DY (2003) Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (troxatyl) and cytarabine in human leukemia cells. Cancer Chemother Pharmacol, 52:6, pp. 497-506.
26. Orsolic, N. (2004) Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: Preclinical evaluation. Br J Haematol, 124:6, pp. 727-738.
27. Belanger, K. (2002) Phase I and pharmacokinetic study of novel -nucleoside analog troxacitabine given as a 30 minutes infusion every 21 days. J Clin Oncol, 20:10, pp. 2567-2574.
28. Gibaldi, M. and Perrier, D. (1982) Pharmacokinetics, pp. 409-417. Marcel Dekker, New York, NY
29. Canova, A., Yee, L. and Baker, S. (1999) A phase I and pharmacokinetic study of beta--dioxalo-cytidine (BCH-4556) administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol, 18, p. 197.
30. Stephenson, JJR, Baker, SD and Aylesworth, C. (1998) A phase I and pharmacokinetic study of BCH-4556, a novel -nucleoside antimetabolite, on a daily × 5 day every 21-day schedule in patients with solid neoplasms. Ann Oncol, 9, p. 156.
31. Baker, SD, Stephenson, JJR and Goetz, A. (1999) Determinants affecting beta-dioxoalne-cytidine (BCH-4556) exposure and relationship with toxicity in phase I trials. Proc Am Soc Clin Oncol, 18, p. 197.
32. Giles, FJ (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol, 19:3, pp. 762-771.
33. Giles, FJ (2002) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol, 20:3, pp. 656-664.
34. Lee, CKK (2006) Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res, 12, pp. 2158-2165.
35. de Bono, JS (2002) Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol, 20:1, pp. 96-109.
36. Giles, FJ (2003) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res, 27:12, pp. 1091-1096.
37. Townsley, CA (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol, 21:8, pp. 1524-1529.
38. Alvarado, Y. (2002) Troxacitabine activity in extramedullary myeloid leukemia. Hematology, 7:3, pp. 179-185.
39. Giles, FJ (2003) Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol, 21:6, pp. 1050-1056.
40. Giles, FJ (2003) Adaptive randomized study of idarubicin and cytarabine vs. troxacitabine and cytarabine vs. troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol, 21:9, pp. 1722-1727.
41. Giles, F. (2002) Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol, 108:3, pp. 164-167.
42. Gourdeau, H. (2004) Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clin Cancer Res, 10:22, pp. 7692-7702.
43. Feldman, EJ, Roboz, GJ and Allen-bard, SL (2003) Phase I evaluation of troxacitabine administered by continuous infusion in subjects. Blood, 873
44. Roboz, GJ (2005) Troxacitabine administered by continuous infusion (CI) is well tolerated and effective in adults with relapsed or refractory acute myeloid leukaemia (AML). J Clin Oncol, 23, p. 584.
45. Vukelja, SJ, Lombardo, FA and James, WD (1989) Pyridoxine for the palmar-plantar erthrodysesthesia syndrome. Ann Intern Med, 111, pp. 688-689.
46. Lopez, AM, Wallace, L. and Dorr, RT (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol, 44, pp. 303-306.